|Offre||78,00 x 1100|
|Vente||78,02 x 1100|
|Var. jour||77,28 - 78,14|
|Sur 52 semaines||57,17 - 89,74|
|Volume moyen||5 524 477|
|Bêta (mensuel sur 5 ans)||0,40|
|Rapport P/E (sur 12 mois)||17,27|
|BPA (sur 12 mois)||4,52|
|Date de bénéfices||31 juil. 2023 - 04 août 2023|
|Dividende et rendement à terme||3,00 (3,94 %)|
|Date ex-dividende||14 juin 2023|
|Objectif sur 1 an||91,38|
NORHAMPTON, MA / ACCESSWIRE / November 10, 2022 / Gilead Sciences While Jesse Garcia was growing up in Chicago's inner city, his parents didn't immediately turn to a doctor when someone in the family got sick. "We relied on traditional Latino ...
NORTHAMPTON, MA / ACCESSWIRE / November 2, 2022 / Gilead Sciences Since the beginning of the COVID-19 pandemic, Gilead's first-in-class antiviral was made available to more than 11 million patients globally- over 65% of whom live in low-and lower-middle-income ...
In the spring of 2018, North Carolina native Stephanie Walker went to her first breast cancer conference and had a revelation that she refers to as her "coming-out party." She learned she had metastatic breast cancer three years earlier and although she was a retired hospice nurse, she faced the disease without any guidance from others who shared her experience.
Gilead Sciences, Inc. (Nasdaq:GILD) recently announced that the Gilead Foundation's Creating Possible Fund™ will provide a total of $20 million to 13 inaugural grantees. The Creating Possible Fund was launched to support creative and high-impact strategies that advance health through education equity, with a main focus on building a pipeline of Black health leaders.